Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $429.8 million.

  • Arrowhead Pharmaceuticals' Non-Current Assets fell 301.61% to $429.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 9.97%. This contributed to the annual value of $434.7 million for FY2025, which is 217.74% down from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Non-Current Assets stood at $429.8 million, which was down 301.61% from $434.7 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Non-Current Assets' 5-year high stood at $444.3 million during Q3 2024, with a 5-year trough of $170.0 million in Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $337.4 million (2023), whereas its average is $353.2 million.
  • Within the past 5 years, the most significant YoY rise in Arrowhead Pharmaceuticals' Non-Current Assets was 7105.48% (2021), while the steepest drop was 3104.75% (2021).
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Non-Current Assets stood at $300.3 million in 2021, then increased by 5.4% to $316.5 million in 2022, then increased by 22.72% to $388.4 million in 2023, then increased by 14.1% to $443.2 million in 2024, then decreased by 3.02% to $429.8 million in 2025.
  • Its last three reported values are $429.8 million in Q4 2025, $434.7 million for Q3 2025, and $433.7 million during Q2 2025.